In prostate cancer patients, PET/CT scans performed with both radiopharmaceuticals are of comparable diagnostic accuracy, although some studies indicated a higher number of unspecific findings in the case of [18F]PSMA-1007 [31,32]. Here, FOLH1 is linked to prostate cancer.